Skip to main content

Table 5 Study inclusion criteria

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Criteria

Definition

Population

Patients infected with hepatitis C virus (HCV) not co-infected with HIV.

Intervention

Pegylated interferon alfa – 2a plus ribavirin (RBV)

Comparator

Pegylated interferon alfa – 2b plus ribavirin

Outcome

Sustained Virological Response (SVR)

Study type

Randomized controlled trials

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us